Clinical Trials Directory

Trials / Completed

CompletedNCT02612948

Quetiapine for Delirium Prophylaxis in High-risk Critically Ill Patients

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
82 (actual)
Sponsor
University of Tennessee Graduate School of Medicine · Academic / Other
Sex
All
Age
18 Years – 100 Years
Healthy volunteers
Accepted

Summary

Scheduled, low-dose quetiapine is effective in preventing delirium in high-risk critically ill, trauma/surgical patients. Prophylaxis also reduced ventilator duration and ICU length of stay.

Detailed description

Objective: To evaluate the efficacy of scheduled quetiapine for delirium prophylaxis in critically ill, trauma/surgical patients identified as high-risk for delirium utilizing a validated prediction model. Design: Prospective, open-label, single-center study. Setting: Trauma/surgical intensive care unit at an academic medical center. Patients: Eighty two adult trauma/surgical patients who were admitted to the intensive care unit and were at high-risk for the development of delirium (PRE-DELIRIC Score ≥50%, past medical history of dementia, past medical history of alcohol misuse, or past medical history of drug abuse). Interventions: Patients were randomized by unit location to receive pharmacologic prophylaxis for delirium (quetiapine 12.5 mg every 12 hours) or no pharmacologic prophylaxis for delirium within forty-eight hours of admission to the intensive care unit. Measurements: The primary end point was the incidence of delirium during admission to the intensive care unit (ICU). Secondary end points included time to onset of delirium, ICU and hospital lengths of stay, ICU and hospital mortality, duration of mechanical ventilation, and adverse events. Delirium was assessed using the confusion assessment method for the intensive care unit.

Conditions

Interventions

TypeNameDescription
DRUGQuetiapineescalating dose to prevent delerium.

Timeline

Start date
2013-11-01
Primary completion
2014-06-01
Completion
2014-06-01
First posted
2015-11-24
Last updated
2015-11-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02612948. Inclusion in this directory is not an endorsement.